{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:38:32Z","timestamp":1790537912813,"version":"4.1.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T00:00:00Z","timestamp":1499299200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T00:00:00Z","timestamp":1499299200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["NCI CA15083 and CM62205."],"award-info":[{"award-number":["NCI CA15083 and CM62205."]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s12020-017-1359-5","type":"journal-article","created":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T14:48:55Z","timestamp":1499352535000},"page":"220-225","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Phase II trial of pazopanib in advanced\/progressive malignant pheochromocytoma and paraganglioma"],"prefix":"10.1007","volume":"57","author":[{"given":"Sina","family":"Jasim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera J.","family":"Suman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilo","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostandinos","family":"Sideras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill K.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis Paul","family":"Worden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Auchus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith C.","family":"Bible","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,6]]},"reference":[{"key":"1359_CR1","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/S0039-6060(96)80037-7","volume":"120","author":"Q Liu","year":"1996","unstructured":"Q. Liu, G. Djuricin, E.D. Staren, P. Gattuso, V.E. Gould, J. Shen, T. Saclarides, D.B. Rubin, R.A. Prinz, Tumor angiogenesis in pheochromocytomas and paragangliomas. Surgery 120, 938\u2013942 (1996). discussion 933\u2212942","journal-title":"Surgery"},{"key":"1359_CR2","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1034\/j.1600-0463.2003.1110402.x","volume":"11","author":"K Salmenkivi","year":"2003","unstructured":"K. Salmenkivi, P. Heikkila, J. Liu, C. Haglund, J. Arola, VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome. APMIS 11, 458\u2013464 (2003)","journal-title":"APMIS"},{"key":"1359_CR3","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1067\/msy.2002.128613","volume":"132","author":"A Zielke","year":"2002","unstructured":"A. Zielke, M. Middeke, S. Hoffmann, M. Colombo-Benkmann, P. Barth, I. Hassan, A. Wunderlich, L.C. Hofbauer, Q.Y. Duh, VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors. Surgery 132, 1056\u20131063 (2002). discussion 1063","journal-title":"Surgery"},{"key":"1359_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1677\/erc.1.00829","volume":"11","author":"G Eisenhofer","year":"2004","unstructured":"G. Eisenhofer, S.R. Bornstein, F.M. Brouwers, N.K. Cheung, P.L. Dahia, R.R. de Krijger, T.J. Giordano, L.A. Greene, D.S. Goldstein, H. Lehnert et al., Malignant pheochromocytoma: current status and initiatives for future progress. Endocr. Relat. Cancer 11, 423\u2013436 (2004)","journal-title":"Endocr. Relat. Cancer"},{"key":"1359_CR5","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/S0002-9440(10)64400-8","volume":"161","author":"J Favier","year":"2002","unstructured":"J. Favier, P.F. Plouin, P. Corvol, J.M. Gasc, Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am. J. Pathol. 161, 1235\u20131246 (2002)","journal-title":"Am. J. Pathol."},{"key":"1359_CR6","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1210\/jc.2008-1972","volume":"94","author":"C Jimenez","year":"2009","unstructured":"C. Jimenez, M.E. Cabanillas, L. Santarpia, E. Jonasch, K.L. Kyle, E.A. Lano, S.F. Matin, R.F. Nunez, N.D. Perrier, A. Phan et al., Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J. Clin. Endocrinol. Metab. 94, 386\u2013391 (2009)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1359_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1210\/jc.2008-1836","volume":"94","author":"AM Joshua","year":"2009","unstructured":"A.M. Joshua, S. Ezzat, S.L. Asa, A. Evans, R. Broom, M. Freeman, J.J. Knox, Rationale and evidence for sunitinib in the treatment of malignant paraganglioma\/pheochromocytoma. J. Clin. Endocrinol. Metab. 94, 5\u20139 (2009)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1359_CR8","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S1470-2045(10)70203-5","volume":"11","author":"KC Bible","year":"2010","unstructured":"K.C. Bible, V.J. Suman, J.R. Molina, R.C. Smallridge, W.J. Maples, M.E. Menefee, J. Rubin, K. Sideras, J.C. Morris 3rd, B. McIver et al., Endocrine Malignancies Disease Oriented Group, Mayo Clinic Cancer Center; Mayo Phase 2 Consortium, Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 11, 962\u2013972 (2010)","journal-title":"Lancet Oncol."},{"key":"1359_CR9","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1210\/jc.2012-2356","volume":"97","author":"M Ayala-Ramirez","year":"2012","unstructured":"M. Ayala-Ramirez, C.N. Chougnet, M.A. Habra, J.L. Palmer, S. Leboulleux, M.E. Cabanillas, C. Caramella, P. Anderson, A. Al Ghuzlan, S.G. Waguespack et al., Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J. Clin. Endocrinol. Metab. 97, 4040\u20134050 (2012)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1359_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2217\/ije-2016-0015","volume":"3","author":"AC Sina Jasim","year":"2016","unstructured":"A.C. Sina Jasim, K.C. Bible, Durable response to lenvatinib in progressive, therapy-refractory, metastatic paraganglioma. Int. J. Endocrine Oncol. 3, 285\u2013289 (2016)","journal-title":"Int. J. Endocrine Oncol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-017-1359-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-017-1359-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-017-1359-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T13:18:45Z","timestamp":1589894325000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-017-1359-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,6]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["1359"],"URL":"https:\/\/doi.org\/10.1007\/s12020-017-1359-5","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,6]]},"assertion":[{"value":"28 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}